 | | |
|
|
|
|
|
|
News
Release: April 24, 2006
Antares Pharma Announces New Proprietary Dermatological Drug Delivery System
EXTON, Pa.--(HSMN NewsFeed)--April 24, 2006--Antares Pharma Inc. (Amex:AIS ) announced today the development of the TecTix(TM) drug delivery system for topical and transmucosal delivery of active pharmaceutical agents. The TecTix system is based on transiently reducing the melting point of an active drug by using a combination of known chemical compounds as special permeation enhancers. Reducing the melting point of a drug with our TecTix system, typically results in increased skin permeation, which in the near term should allow Antares to develop novel products specifically targeted for proprietary dermatological and mucosal delivery applications.
Our TecTix system has been successfully tested in vitro on numerous drug models, including AP-1118, a local anaesthetic where concentration in the dermis was increased by +236%, improving the topical to systemic absorption ratio. The benefits of TecTix have also been confirmed in AP-1110, another of our local skin anaesthetics where the melting point was decreased by more than 50 degrees C, causing it to spontaneously melt at room temperature.
In addition to its potential compatibility with numerous active drugs and superior melting point depressant effect, the TecTix system also is believed to possess several unique efficacy characteristics in delivering drug substances to specific areas of the skin or mucosa. Patent applications have also been filed on behalf of the TecTix system.
Dario Carrara, Ph.D., Managing Director for Antares Pharma's Pharmaceutical operations, commented, "The very promising results obtained from pre-clinical testing support our belief that the TecTix system can be successfully applied to numerous therapeutic areas. As a substantially alcohol-free delivery system, TecTix appears to be a perfect match for dermatological products targeting different layers of the skin or mucosa, without utilizing potentially irritating excipients."
Mr. Jack Stover, President and CEO of Antares Pharma added, "The TecTix system provides Antares with another significant complement to its ATD(TM) Advanced Transdermal Delivery system platform and further enhances our intellectual property portfolio and growing product pipeline."
About Antares Pharma
Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares' current system platforms include its recently announced TecTix(TM) system for topical and transmucosal delivery, ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM) oral fast-melt system, and subcutaneous injection system platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM)/VisionŽ reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience.
Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
|
Source: Antares Pharma
Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.
|
 |
|
|
Public
Feeds 
